Published in J Hepatol on June 01, 2003
ADPKD Alterations in Hepatic Transporter Function | NCT03717883
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
Bile acid transporters. J Lipid Res (2009) 2.31
Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch (2006) 1.58
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci U S A (2005) 1.57
Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev (2010) 1.52
The bile salt export pump. Pflugers Arch (2006) 1.34
Bile formation and secretion. Compr Physiol (2013) 1.32
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A (2006) 1.27
Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci (2008) 1.20
ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol Sci (2009) 1.18
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol (2009) 1.07
The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis (2010) 1.07
Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci (2009) 1.04
New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol (2006) 1.03
Ductal plates in hepatic ductular reactions. Hypothesis and implications. III. Implications for liver pathology. Virchows Arch (2011) 0.99
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch (2013) 0.97
Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev (2010) 0.93
Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis (2010) 0.93
Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes. Toxicol Appl Pharmacol (2012) 0.93
Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis (2013) 0.91
An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci (2013) 0.89
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos (2013) 0.89
Molecular mechanisms of cholestasis. Wien Med Wochenschr (2006) 0.88
Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med (2013) 0.87
The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol Int (2009) 0.86
New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol (2013) 0.85
The bile salt export pump: molecular properties, function and regulation. Pflugers Arch (2004) 0.83
Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. Am J Physiol Gastrointest Liver Physiol (2007) 0.81
Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology (2013) 0.81
The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response. Dis Markers (2014) 0.81
Oral administration of oleanolic acid, isolated from Swertia mussotii Franch, attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats. Int J Clin Exp Med (2015) 0.80
Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos (2013) 0.80
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf (2016) 0.79
Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstruction. PLoS One (2015) 0.79
Altered alkaline phosphatase activity in obese Zucker rats liver respect to lean Zucker and Wistar rats discussed in terms of all putative roles ascribed to the enzyme. Eur J Histochem (2011) 0.78
Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch (2007) 0.78
Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene. Drug Metab Dispos (2014) 0.77
Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. J Histochem Cytochem (2005) 0.77
Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR. J Immunol Res (2015) 0.77
Swertianlarin, isolated from Swertia mussotii Franch, increases detoxification enzymes and efflux transporters expression in rats. Int J Clin Exp Pathol (2015) 0.76
Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis. Int J Clin Exp Pathol (2015) 0.75
Dioscin Protects ANIT-Induced Intrahepatic Cholestasis Through Regulating Transporters, Apoptosis and Oxidative Stress. Front Pharmacol (2017) 0.75
Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension. Exp Ther Med (2016) 0.75
A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Increased Renal Clearance of Rocuronium Compensates for Chronic Loss of Bile Excretion, via upregulation of Oatp2. Sci Rep (2017) 0.75
Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis (2014) 0.75
Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J Gastroenterol (2006) 0.75
Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci (2017) 0.75
Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.75
Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70
Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA (2011) 4.21
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
Sedation in screening colonoscopy: impact on quality indicators and complications. Am J Gastroenterol (2012) 2.97
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
Biobanking for Europe. Brief Bioinform (2007) 2.76
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45
von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology (2012) 2.36
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One (2010) 2.10
Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One (2009) 2.04
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol (2012) 1.81
Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (2013) 1.77
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm (2006) 1.72
Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology (2013) 1.71
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol (2007) 1.70
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol (2008) 1.68
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Comprehensive catalog of European biobanks. Nat Biotechnol (2011) 1.64
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol (2005) 1.64
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol (2006) 1.63
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta (2006) 1.57
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer (2003) 1.53
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int (2008) 1.52